Protocol Number: 04-C-0218
Patients 18 years of age and older with a solid tumor cancer or lymphoma for which effective standard treatments are not available may be eligible for this study. Upon enrollment, participants are evaluated with a medical history and physical examination, blood and urine tests, electrocardiogram (EKG) and chest X-ray, diagnostic imaging studies (CT or MRI) to assess the extent of the cancer. In addition, patients undergo the following tests and procedures: -17-DMAG treatment - 17-DMAG doses are infused through a vein twice a week for 4 weeks, unless too many side effects develop. Each infusion lasts about 1 hour. Treatment may continue beyond 4 weeks in patients whose tumor does not grow and who do not experience severe side effects. After 8 weeks of treatment, the patient's response to the drug is evaluated with a physical examination, scans, and X-rays. -Blood studies - Blood work includes the following: 2 tablespoons of blood is drawn twice a week (before each drug dose) to assess how kidney, liver, bone marrow, and clotting mechanisms are functioning. 13 tablespoons of blood is drawn twice during the first 4 weeks of treatment to look for drug effects in the blood. On the first day of 17-DMAG treatment, 1 to 2 teaspoons of blood is drawn before the drug infusion, after the infusion is finished, and another 10 times over the next 48 hours to examine how the body breaks down and eliminates the drug. -24-hour urine collection - On the first day of 17-DMAG treatment, patients collect all their urine for 24 hours after the drug infusion to study how the body breaks down and eliminates the drug. -Imaging studies - X-rays and scans are done to evaluate the size and extent of tumor. -Tumor biopsy - If it can be done safely, a small piece of tumor is surgically removed before treatment starts and again during the first week of treatment and the fourth week of treatment to examine the effects of 17-DMAG on the tumor.
Search The Studies | Help | Questions |
National Institutes of Health Clinical Center |
||